Your browser doesn't support javascript.
loading
Prophylactic tocilizumab reduces the incidence of cytokine release syndrome in relapsed/refractory myeloma patients treated with teclistamab: Implications for outpatient step-up dosing.
Korst, Charlotte L B M; Groen, Kaz; Bosman, Patricia W C; van der Valk, Fleur; Verkleij, Christie P M; Kruyswijk, Sandy; de Ruijter, Maaike E M; Heijink, Dianne M; Kuipers, Maria T; Zweegman, Sonja; van de Donk, Niels W C J.
Afiliación
  • Korst CLBM; Department of Hematology, Amsterdam UMC Vrije Universiteit Amsterdam Amsterdam The Netherlands.
  • Groen K; Cancer Biology and Immunology Cancer Center Amsterdam Amsterdam The Netherlands.
  • Bosman PWC; Department of Hematology, Amsterdam UMC Vrije Universiteit Amsterdam Amsterdam The Netherlands.
  • van der Valk F; Cancer Biology and Immunology Cancer Center Amsterdam Amsterdam The Netherlands.
  • Verkleij CPM; Department of Hematology, Amsterdam UMC Vrije Universiteit Amsterdam Amsterdam The Netherlands.
  • Kruyswijk S; Cancer Biology and Immunology Cancer Center Amsterdam Amsterdam The Netherlands.
  • de Ruijter MEM; Department of Hematology Onze Lieve Vrouwe Gasthuis Amsterdam The Netherlands.
  • Heijink DM; Department of Hematology, Amsterdam UMC Vrije Universiteit Amsterdam Amsterdam The Netherlands.
  • Kuipers MT; Cancer Biology and Immunology Cancer Center Amsterdam Amsterdam The Netherlands.
  • Zweegman S; Department of Hematology, Amsterdam UMC Vrije Universiteit Amsterdam Amsterdam The Netherlands.
  • van de Donk NWCJ; Cancer Biology and Immunology Cancer Center Amsterdam Amsterdam The Netherlands.
Hemasphere ; 8(7): e132, 2024 Jul.
Article en En | MEDLINE | ID: mdl-39050549

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Hemasphere Año: 2024 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Hemasphere Año: 2024 Tipo del documento: Article
...